Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
Updates in Muscular Dystrophy: A Focus on DMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Updates in Muscular Dystrophy: A Focus on DMD
close
Restart
Resume
Share this program on:
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Get your free creditsSkip straight to the post-test if you have already participated in this activity
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.Faculty Disclosures
The following faculty report that they have relevant financial relationships to disclose:Crystal Proud, MD has done contract research for Astellas Pharma, Catabasis Pharmaceuticals, PTC, Pfizer, and Sarepta.
Edward Smith, MD has received honoraria and consulted for Edgewise, NS Pharma, Inc., Pfizer, Sarepta, and RegenexBio Inc.
Target Audience
The primary target audience for this activity is neurologists and pediatricians. The secondary target audience is other clinical staff involved in the multidisciplinary management of patients with DMD.
Learning Objectives
Upon completion of this activity, learners should increase their ability to
- Describe the relationship of DMD genetics and pathophysiology
- Describe extramuscular manifestations of DMD, e.g. cognitive, pulmonary, and cardiac
- Explain the importance of early diagnosis of DMD and the challenges associated with making this diagnosis
- Refer to specialists in a timely manner
Accreditation and Credit Designation Statements
ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.CREDIT DESIGNATION
Physicians:
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an independent educational grant from Sarepta Therapeutics, Inc.
Publication Dates
Release Date:
Expiration Date:
Recommended
Details
Presenters
Comments
Recommended
Overview
Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.Faculty Disclosures
The following faculty report that they have relevant financial relationships to disclose:Crystal Proud, MD has done contract research for Astellas Pharma, Catabasis Pharmaceuticals, PTC, Pfizer, and Sarepta.
Edward Smith, MD has received honoraria and consulted for Edgewise, NS Pharma, Inc., Pfizer, Sarepta, and RegenexBio Inc.
Target Audience
The primary target audience for this activity is neurologists and pediatricians. The secondary target audience is other clinical staff involved in the multidisciplinary management of patients with DMD.
Learning Objectives
Upon completion of this activity, learners should increase their ability to
- Describe the relationship of DMD genetics and pathophysiology
- Describe extramuscular manifestations of DMD, e.g. cognitive, pulmonary, and cardiac
- Explain the importance of early diagnosis of DMD and the challenges associated with making this diagnosis
- Refer to specialists in a timely manner
Accreditation and Credit Designation Statements
ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.CREDIT DESIGNATION
Physicians:
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an independent educational grant from Sarepta Therapeutics, Inc.
Publication Dates
Release Date:
Expiration Date:
Facebook Comments